Harrow Acquires TYRVAYA Global Rights, Expands Dry Eye Portfolio
NASHVILLE, Tenn., August 6, 2026 Harrow Inc. announced it has entered into a definitive agreement to acquire the global...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NASHVILLE, Tenn., August 6, 2026 Harrow Inc. announced it has entered into a definitive agreement to acquire the global...
RAANANA, Israel, July 2, 2026 Polyrizon Ltd. announced the successful completion of its NASARIXâ„¢ biocompatibility evaluation program, marking an...
San Diego, U.S. | April 15, 2026 ARS Pharmaceuticals has achieved a major regulatory milestone with Health Canada approval...
